PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions

PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions

PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLCПодробнее

PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLC

The importance of understanding the patient perspective in evaluating treatment efficacyПодробнее

The importance of understanding the patient perspective in evaluating treatment efficacy

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLCПодробнее

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

Mutaciones EGFR en Axon 20 y Amivantanab: Diagnóstico y Tratamiento en NSCLC MetastásicoПодробнее

Mutaciones EGFR en Axon 20 y Amivantanab: Diagnóstico y Tratamiento en NSCLC Metastásico

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLCПодробнее

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC